Comprehensive pan-cancer in tumors of human with tumor suppressor ZMYND11 gene

Abstract

Abstract Background ZMYND11 is a reader of histone proteins and plays an important inhibition role in tumor. There is growing evidence to support its importance, but without a pan-cancer analysis, Based on multiple databases, we conducted a comprehensive analysis. Methods Tumor data from both The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were a clear relationship observed gene expression of ZMYND11, state of survival, induction of DNA methylation, alterations in genes, contribution to the parameter of protein phosphorylation, lymphocyte immune infiltration, and correlative cellular pathways. Results ZMYND11 was under-expressed in the great majority of carcinomas. High expression group of ZMYND11 offers a more favorable prognosis in KIRC, LGG, MESO, LUAD,PRAD,READ,THCA,BRCA, SARC and UVM. Alterations in N304Kfs*33, K345Rfs*43 and N271Tfs*18 occur in structurally important domains of ZMYND11 and was found in prostate, colorectal and breast cancers.In most tumour tissues, ZMYND11 promoter DNA methylation was lower than in normal tissues, and promoter methylation was largely negatively correlated with mRNA expression levels. We observed low levels of phosphorylation at locus 349 protein in KIRC were identified with low total ZNYND11 protein expression. High phosphorylation levels at locus 393 protein in breast cancer with high total ZNYND11 protein expression. ZMYND11 gene expression in human tumors is mostly reflected by positively relation to immune cell infiltration while it is confirmed by positive association with CD8 + T cell. There was a differential expression of ZMYND11 in different immune subtypes. The gene enrichment SOSO2, PJA2 and KIAA1109 may be molecules interacting with ZMYND11.KEGG and GO analysis involving in RNAase II promoter regulation, positive and negative regulation of the RNAase II promoter, positive and negative regulation of DNA transcription, chromatin modification. Conclusions This is a comprehensive pan-cancer analysis of the ZMYND11. It describes the role of ZMYND11 in tumour. and highlights a potential target for ZMYND11 in tumour.